Welcome to our library! Here you will find IDB publications on Health Technology Assessment (HTA), Health Benefit Plans (HBP), pharmaceutical policy, drugs and medical devices regulation, catastrophic funds, and horizon scanning, among others. We classify our publications into three categories: books, policy documents, and technical notes.
The collection presented here contains all our English publications. If you would like to access our full collection of publications, please visit the Spanish version of our website by changing the language in the upper right corner of this site.
The following Breve provides an overview of the main challenges that societies, health care systems, and policy makers are currently facing to confront cancer. This brief analyzes the main characteristics of cancer, and shows how these influence the development of new drugs. At the same time, it looks at some of the implications for patients. It also presents some thoughts on the pharmaceutical industry related to cancer treatments. Finally, it summarizes some policy lessons emerging from the analysis, and explains why basic research, better market regulation and a stronger focus on cancer prevention should be the main priorities to fight cancer in the future.
This Breve is based on a webinar presented by Jonathan Dartnell and Aine Heaney, at NPS MedicineWise, on August 18 of 2015, to the members of CRITERIA, the IDB Knowledge Network on Health Benefits Packages and Priority Setting in Health.
This Breve is based on a webinar presented by Tommy Wilkinson, Health Economics Advisor at NICE International, on April, 2014, to the members of CRITERIA, the Knowledge Network on Health Benefits Packages and Priority Setting in Health. Two prime examples of explicit priority setting in the healthcare space can be found in the United Kingdom and New Zealand. The UK's National Institute for Health and Care Excellence (NICE) and its achievements are recognized around the world. New Zealand's Pharmaceutical Management Agency (PHARMAC) has a similar remit to NICE, in that it determines funded access to pharmaceuticals and other technologies while operating within a range of different constraints and contexts. For many, PHARMAC also represents one of the world's most successful case studies in medical priority setting and pharmaceutical expenditure control.
The presentation and its resulting BREVE provide a perspective on the objectives, capacities and products of NICE2 and PHARMAC and explore the comparative advantages of each of these agencies. Specifically, it describes and compares the two agencies and the context in which they work; analyzes and compares their priority setting processes; and presents an overview of the types of Health Technology Assessment (HTA) conducted. Given the relative lack of information currently available in the literature about processes employed by PHARMAC, this policy brief will focus on PHARMAC in greater detail. For full information on NICE and PHARMAC, please refer to their websites www.nice.org.uk and www.pharmac.govt.nz, respectively.
This Breve is based on a webinar presented by Valérie Paris, health economist at the Organization for Economic Cooperation and Development (OECD), on May 15, 2014, to the members of the Knowledge Network on Health Benefits Packages and Priority Setting in Health. The presentation focused on research carried out by the OECD and on data from the 2012 Health System Characteristics Survey. Two studies were specifically referenced: (i) "Value in Pharmaceutical Pricing", published in 2013, which explores the methods used by 14 OECD countries to make decisions on reimbursement and the pricing of pharmaceutical products on the basis of their value; and (ii) an ongoing study that seeks to identify how OECD countries define the health benefits packages covered by their systems. The current brief presents key results emerging from these two studies.
Guaranteeing the right to health care under equal conditions for all is a goal that every society desires to achieve, particularly in a region as unequal as Latin America and the Caribbean. Universal coverage is an important objective for most countries; however, the context for attaining universal coverage is difficult, as the pressure on health spending mounts with each passing day. So, what to leave in or out of a health benefit plan?